全文获取类型
收费全文 | 187401篇 |
免费 | 49686篇 |
国内免费 | 3457篇 |
专业分类
耳鼻咽喉 | 1923篇 |
儿科学 | 8787篇 |
妇产科学 | 843篇 |
基础医学 | 30556篇 |
口腔科学 | 7170篇 |
临床医学 | 21052篇 |
内科学 | 39707篇 |
皮肤病学 | 4987篇 |
神经病学 | 19665篇 |
特种医学 | 7809篇 |
外国民族医学 | 10篇 |
外科学 | 42174篇 |
综合类 | 10334篇 |
现状与发展 | 17篇 |
一般理论 | 11篇 |
预防医学 | 9643篇 |
眼科学 | 2621篇 |
药学 | 13397篇 |
24篇 | |
中国医学 | 4777篇 |
肿瘤学 | 15037篇 |
出版年
2024年 | 178篇 |
2023年 | 1427篇 |
2022年 | 2205篇 |
2021年 | 5044篇 |
2020年 | 8919篇 |
2019年 | 14299篇 |
2018年 | 13811篇 |
2017年 | 14778篇 |
2016年 | 13943篇 |
2015年 | 13805篇 |
2014年 | 15591篇 |
2013年 | 16329篇 |
2012年 | 13852篇 |
2011年 | 14519篇 |
2010年 | 12797篇 |
2009年 | 9369篇 |
2008年 | 9993篇 |
2007年 | 8548篇 |
2006年 | 8221篇 |
2005年 | 7497篇 |
2004年 | 6781篇 |
2003年 | 5975篇 |
2002年 | 5362篇 |
2001年 | 4299篇 |
2000年 | 2797篇 |
1999年 | 1394篇 |
1998年 | 1073篇 |
1997年 | 927篇 |
1996年 | 893篇 |
1995年 | 760篇 |
1994年 | 804篇 |
1993年 | 514篇 |
1992年 | 616篇 |
1991年 | 476篇 |
1990年 | 337篇 |
1989年 | 355篇 |
1988年 | 315篇 |
1987年 | 239篇 |
1986年 | 198篇 |
1985年 | 214篇 |
1984年 | 203篇 |
1983年 | 97篇 |
1982年 | 135篇 |
1981年 | 124篇 |
1980年 | 101篇 |
1979年 | 86篇 |
1978年 | 79篇 |
1977年 | 67篇 |
1976年 | 65篇 |
1975年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《European journal of surgical oncology》2022,48(3):621-631
ObjectivesThe aim of this meta-analysis was to conduct a contemporary systematic review of high quality non-randomised controlled trials to determine the effect of pre-liver transplantation (LT) transarterial chemoembolisation (TACE) on long-term survival and complications of hepatocellular carcinoma (HCC) patients.BackgroundTACE is used as a neoadjuvant therapy to mitigate waitlist drop-out for patients with HCC awaiting LT. Previous studies have conflicting conclusions on the effect of TACE on long-term survival and complications of HCC patients undergoing LT.MethodsCINAHL, Cochrane Controlled Register of Trials, Embase, PubMed, and Web of Science were systematically searched. Baseline characteristics included number of patients outside Milan criteria, tumour diameter, MELD score, and time on the waiting list. Primary outcomes included 3- and 5-year overall and disease-free survival. Secondary outcomes included tumour recurrence, 30-day postoperative mortality, and hepatic artery and biliary complications.ResultsTwenty-one high-quality NRCTs representing 8242 patients were included. Tumour diameter was significantly larger in TACE patients (3.49 cm vs 3.15 cm, P = 0.02) and time on the waiting list was significantly longer in TACE patients (4.87 months vs 3.46 months, P = 0.05), while MELD score was significantly higher in non-TACE patients (10.81 vs 12.35, P = 0.005). All primary and secondary outcomes displayed non-significant differences.ConclusionPatients treated with TACE had similar survival and postoperative outcomes to non-TACE patients, however, they had worse prognostic features compared to non-TACE patients. These findings strongly support the current US and European clinical practice guidelines that neoadjuvant TACE can be used for patients with longer expected waiting list times (specifically >6 months). Randomised controlled trials would be needed to increase the quality of evidence. 相似文献
2.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献
3.
4.
5.
6.
7.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
8.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
9.